Becotatug vedotin

维贝柯妥塔单抗

Report date: 2026/05/15 20:01:45

Base Information

Drug NameBecotatug vedotin
Drug Alias Name美佑恒MRG-003MRG003
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payload
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonistsApoptosis inhibitorsMitosis inhibitors +[5] 
TargetsEpidermal growth factor receptor erbB1Tubulin
Therapy Area/IndicationsLymphoepithelial carcinomaSolid tumoursPenile Neoplasms +[28] 
Global Approved IndicationsNasopharyngeal Carcinoma
Approved Indications in ChinaNasopharyngeal Carcinoma
Original Approved Country/TerritoryMainland China
Original Approved Date2025/10/28
Country/TerritoryUnited StatesEUMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShanghai Miracogen Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesLepu Medical Technology (Beijing) Co LtdWuhan Union HospitalFudan University +[8] 
Inactive CompaniesN/A
Active IndicationsLymphoepithelial carcinomaSolid tumoursPenile Neoplasms +[27] 
Inactive IndicationsEsophageal Neoplasms

Other Information

ATC CodeN/A
Related LinksDrugBank